Scholar Rock CEO says ISEMBYLD demand is steady as payer steps push most first infusions into 2027, at Jefferies London
Scholar Rock chief executive David Hallal told the Jefferies Global Healthcare Conference in London that weekly enrollment for its SMA drug ISEMBYLD has been steady since its September approval, but that most patients enrolled so far are likely to start treatment in early 2027.
